What do the next 100 years hold for pneumococcal vaccination?

Rijkers, Ger T.; Mens, Suzan P. van; Velzen‐Blad, Heleen van

doi:10.1586/erv.10.127

Cited by 12 publications

(7 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…As recently described by Rijkers et al 32 pneumococcal vaccines may become the most important vaccines for adults and children worldwide in the future years. Healthcare providers and key decision makers should recognize the serious health impact of pneumococcal disease in adults, closely monitor the epidemiology of pneumococcal serotypes, particularly 'serotype replacement' and ensure increased vaccine coverage.…”

Section: Resultsmentioning

confidence: 87%

Cost-effectiveness analysis of pneumococcal polysaccharide vaccination from age 60 in São Paulo State, Brazil

et al. 2011

View full text Add to dashboard Cite

Section: Resultsmentioning

confidence: 87%

Cost-effectiveness analysis of pneumococcal polysaccharide vaccination from age 60 in São Paulo State, Brazil

et al. 2011

View full text Add to dashboard Cite

“… 41 – 43 These vaccines incorporate more of the most predominant serotypes, including the replacement serotypes ( Figure 2 ). 44 – 46 Also, after introduction of PCV13, serotype replacement continues. Across Europe, 24F and 15A now are the emerging serotypes not included in the PPSV23.…”

Section: Pneumococcal Vaccines and Vaccinationmentioning

confidence: 99%

Triptych of the Hermit Saints: pneumococcal polysaccharide vaccines for the elderly

Rijkers

Yousif

Spoorenberg

et al. 2018

RMHP

View full text Add to dashboard Cite

Pneumococcal pneumonia is a serious disease with considerable morbidity and mortality in the elderly. Despite adequate antibiotic treatment, the long-term mortality of pneumococcal pneumonia remains high. Preventive measures in the form of vaccination, therefore, are warranted. Twenty-three-valent polysaccharide vaccines have a broad coverage but limited efficacy. Pneumococcal conjugate vaccines have been shown in children to be able to prevent invasive and mucosal pneumococcal diseases. It should be realized that the serotype composition of current pneumococcal conjugate vaccines is not tailored for the elderly, and that replacement disease can occur. Yet, the current 13-valent conjugate vaccine has been shown to protect against infections with vaccine serotypes. Long-term mortality of pneumococcal pneumonia should be included in policy making about the introduction of these vaccines for the elderly.

show abstract

“…There is a potential risk of invasive pneumococcal disease occurring due to these non-PCV 7 serotypes some of which may be resistant to routinely used antibiotics [50,51]. This concern has now led to including these non-PCV 7 serotypes in the recently manufactured pneumococcal conjugate vaccines, namely, the 11-valent pneumococcal conjugate vaccine (PCV-11) and the 13-valent pneumococcal conjugate vaccine (PCV-13) [52].…”

Section: Pneumococcal Conjugate Vaccinementioning

confidence: 99%

Update on Available Vaccines in India: Report of the APPA VU 2010: I

Karande

2011

Indian J Pediatr

View full text Add to dashboard Cite

The Asia Pacific Pediatric Association Vaccinology Update 2010 was held in Mumbai on November 13-14, 2010 to discuss the latest information on burden of infectious diseases, recent developments in vaccines and their impact on immunization practices against infectious diseases occurring in Indian children. During the conference the importance of including conjugate Haemophilus influenzae type b vaccine and anti-rabies vaccines in routine immunization was stressed. Also, the need for giving a second dose of measles mumps rubella vaccine at school entry; and the need for a two-dose varicella vaccine regimen (first dose at 12-15 months of age and a second dose at age 4-6 years) was elucidated. Information related to vaccines which have become available in India in recent years, namely, inactivated poliovirus vaccine; diphtheria, tetanus, acellular pertussis (DTaP) vaccine; conjugate pneumococcal vaccine; rotavirus vaccines; H1N1 vaccines; live attenuated hepatitis A virus vaccine; oral cholera vaccine; tetanus, reduced-dose diphtheria, acellular pertussis (Tdap) vaccine; and human papillomavirus vaccines were discussed.

show abstract

What do the next 100 years hold for pneumococcal vaccination?

Cited by 12 publications

References 40 publications

Cost-effectiveness analysis of pneumococcal polysaccharide vaccination from age 60 in São Paulo State, Brazil

Cost-effectiveness analysis of pneumococcal polysaccharide vaccination from age 60 in São Paulo State, Brazil

Triptych of the Hermit Saints: pneumococcal polysaccharide vaccines for the elderly

Update on Available Vaccines in India: Report of the APPA VU 2010: I

Contact Info

Product

Resources

About